Monthly Archives: October 2008

New, more efficient anti-AIDS drug for untreated patients

October 31st, 2008|

Medical researchers unveiled clinical trials of new anti-AIDS drug that better controls the spread of the deadly virus among previously untreated patients. 

UCB’s Vimpat(R) gets approval by U.S. FDA

October 31st, 2008|

UCB announced that the U.S. Food and Drug Administration (FDA) has approved Vimpat® (lacosamide), a new antiepileptic drug (AED). Vimpat® is for use as an add-on therapy for the treatment of partial-onset seizures in people with epilepsy who are 17 years and older. 

New Mexico Software’s XR-Express gets U.S. FDA Clearance

October 31st, 2008|

New Mexico Software, Inc., a leading services provider of next-generation business and medical products, announced today that the company has obtained 510(k) clearance for its XR-EXpress Picture Archiving and Communication System (PACS) from the U.S. Food and Drug Administration (FDA). 

NAFDAC bans 22 Fake Drug Manufacturers

October 31st, 2008|

The National Agency for Food and Drug Administration and Control (NAFDAC) has banned 22 firms that it says are involved in the manufacture of fake drugs from ever again selling pharmaceuticals in Nigeria, as part of a countrywide clampdown. 

J&JPRD submits Carisbamate NDA to US FDA

October 31st, 2008|

Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) has submitted a New Drug Application to the US Food and Drug Administration (FDA) for carisbamate, a new investigational compound for the adjunctive treatment of partial onset seizures in patients 16 years of age and older. 

BioTrove and Agilent partners for mass spectrometry

October 31st, 2008|

Agilent and BioTrove have forged a non-exclusive mass spectrometry partnership designed to enhance the screening of candidate drug compounds in early stage development. 

Bharat Biotech to develop Biotech-Pharma-IT park in Orissa

October 31st, 2008|

Bharat Biotech International Ltd (BBIL), a producer of vaccines and biotherapeutics announced that the Orissa government has selected the company as the developer for its ‘Biotech-Pharma-IT Park’ project under public-private-partnership (PPP) mode. 

Positive Phase 2 Study Results for Next Generation Oxazolidinone

October 27th, 2008|

Rib-X Pharmaceuticals, Inc., a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive results from a Phase 2 clinical trial with the oral form of its compound, radezolid (RX-1741), for the treatment of uncomplicated skin and skin structure infections (uSSSI). 

Pfizer’s Selzentry(TM) (Maraviroc) shows greater Efficacy Rate

October 27th, 2008|

Patients taking Selzentry, in combination with Combivir® (zidovudine/lamivudine) and selected by an enhanced sensitivity tropism test to screen patients, experienced a 68 percent rate of virologic suppression to undetectable levels, according to the MERIT ES. 

Pegloticase may treat gout – Study

October 27th, 2008|

The Savient Pharmaceuticals drug, called pegloticase, helped remove uric acid, which causes the painful, needle-like crystals that clump around fingers, toes and other joints in the condition. 

Incyte’s JAK Inhibitor shows clinical Improvement in Rheumatoid Arthritis Patients

October 27th, 2008|

Incyte Corporation announced the presentation of clinical results from a 28-day Phase IIa trial of INCB18424, its orally available janus kinase (JAK) inhibitor, in patients with rheumatoid arthritis (RA). 

Glenmark Pharmaceuticals Q2 net up 56%

October 27th, 2008|

Drug-maker Glenmark’s net profit for the second quarter ended 30 September grew by 56.23% at Rs117.36 crore over the corresponding period a year ago. 

European CHMP adopts negative opinion on Cymbalta

October 27th, 2008|

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a negative opinion on a Cymbalta® (duloxetine hydrochloride) application for the treatment of fibromyalgia. 

Maharashtra Stays at Top

October 27th, 2008|

Maharashtra, the cradle of the Indian pharmaceutical industry, continues to maintain its domination in this field…….[English]-[French]-[Spanish]

US FDA Approval for Bronchial Valve of Spiration, Inc.

October 26th, 2008|

Humanitarian Device Exemption Allows IBV(R) Valve System As Minimally Invasive Treatment Alternative for Patients with Prolonged Post-Operative Air Leaks. 

NeurogesX seeks US FDA marketing approval for dermal capsaicin patch for pain

October 26th, 2008|

NeurogesX, Inc, a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has submitted a new drug application (NDA) with the US Food and Drug Administration (FDA) for approval to market its investigational product candidate, NGX-4010, for the management of pain due to postherpetic neuralgia (PHN). 

GSK’ Alli gets positive CHMP opinion for weight loss treatment

October 26th, 2008|

GlaxoSmithKline (GSK) has received a positive opinion from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) for Alli (Orlistat 60mg) as a non-prescription product. 

GSK buys Biotene brand for $170 million

October 26th, 2008|

GlaxoSmithKline is buying Biotene, the top dry mouth brand, from privately held Laclede for $170 million to strengthen its therapeutic oral healthcare portfolio. 

India collaborate with Russia in nanotechnology research

October 26th, 2008|

India and Russia will now take forward the collaborative science programmes to new areas like ocean research, gas hydrides for energy security and nanotechnology and work for transfer of technology for industry. The research in the emerging areas would help India achieve energy security and use technology for the benefit of the public. 

Immunocellular gets US patents for monoclonal antibody therapeutics October 24, 2008

October 26th, 2008|

ImmunoCellular Therapeutics, Ltd, a biotechnology company, announced the issuance of two separate US patents relating to the company's monoclonal antibody therapeutics. Patents no 7,435,415 and no 7,435,554 are both entitled 'Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer (SCLC)'.